Related Experiment Videos
Neuroprotection for acute stroke: making clinical trials work
1Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland.k.muir@clinmed.gla.ac.uk
Stroke
|January 8, 1999
Summary
To improve stroke clinical trial success, focus on middle cerebral artery strokes with a penumbra, identified via imaging. This targeted approach may enhance intervention effectiveness and reduce trial failures.
Area of Science:
- Neurology
- Clinical Trials
- Neuroprotection
Background:
- Most stroke clinical trials, excluding tPA, have yielded negative results.
- Re-evaluation of trial methodology is crucial to prevent further failures in neuroprotection research.
Purpose of the Study:
- To identify optimal patient populations and methodologies for future stroke clinical trials.
- To enhance the success rate of neuroprotective therapies in stroke patients.
Main Methods:
- Analyzing existing stroke trial data and animal models.
- Evaluating the utility of the Oxfordshire Community Stroke Project classification.
- Assessing the role of advanced imaging techniques in identifying stroke penumbras.
- Considering shortened follow-up periods and imaging surrogate endpoints.
Main Results:
- Middle cerebral artery strokes involving the cerebral cortex are a logical target population.
- Imaging techniques can identify a "penumbra" indicating potential for intervention.
- Outcome appears determined in patients without a penumbra.
Conclusions:
- Clinical trials should target patients with large middle cerebral artery strokes and radiological penumbra.
- Imaging may define intervention windows better than time alone and serve as surrogate endpoints.
- This focused approach may offset slower recruitment with extended windows and fewer patients, aiding drug development.